Business
Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update
- Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous
About this update from Liquidia Corporation
[{"type":"text","content":"- Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administration - Preparing to launch YUTREPIA in late-2022 pending final FDA approval - Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., March 17, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for full-year ended December 31, 2021. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2021 financial results and provide a corporate update. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Last year, we achieved every goal we set by increasing sales of Treprostinil Injection, securing tentative approval of YUTREPIA, advancing our legal position in the ongoing Hatch-Waxman case, and strengthening our balance sheet. I am sincerely grateful for the team who has positioned the company for its next stage of dramatic growth. We are excited about the opportunity to offer YUTREPIA to PAH patients in 2022, especially as the demand for inhaled treprostinil expands into a potential market opportunity of over $1 billion in the near future.” Corporate Updates Completed first full year as a fully integrated, research, development, and commercial organization with immediate focus on treating pulmonary hypertension. In November 2020, Liquidia Technologies, Inc. and RareGen, LLC (now known as Liquidia PAH, LLC) became wholly owned operating subsidiaries of Liquidia Corporation. The new corporate entity includes commercialization capabilities and expertise in pulmonary arterial hypertension (PAH) in support of Treprostinil Injection, the first-to-file generic formulation of Remodulin® (treprostinil) from Sandoz Inc. Strategically, the combined entity reinforced Liquidia’s commitment to PAH patients and the medical community in preparation for the launch of YUTREPIA™ (treprostinil) inhalation powder upon potential final approval by the United Stated Food and Drug Administration (FDA) and favorable resolution of the Hatch-Waxman litigation. Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder to treat PAH, validating the application of PRINT® Technology. In November 2021, the FDA issued a tentative approval of YUTREPIA which indicated th...